Overview: Metamyelocytes TestIntroduction: The Metamyelocytes Test counts metamyelocytes to diagnose leukemias or bone marrow disorders, helping identify causes of abnormal blood counts or fatigue. Affecting 1 in 100,000 people with leukemia, metamyelocyte elevation poses diagnostic challenges due to bone marrow involvement. Following 2023 American Society of Hematology (ASH) guidelines, it uses microscopy for high accuracy, supporting hematology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Metamyelocyte Count Test, Bone Marrow Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Metamyelocyte counting began in the 1950s with research by Dameshek, who linked it to leukemia. Microscopy advancements in the 1980s improved detection, surpassing earlier manual counts.
Purpose: Counts metamyelocytes to diagnose leukemias or marrow disorders, guides chemotherapy or supportive care, and evaluates patients with fatigue, aiming to manage disease.
Test Parameters: Metamyelocyte count
Pretest Condition: No special preparation required. Collect whole blood or bone marrow. Report history of blood disorders.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 1-3 mL); 4 mL whole blood in EDTA tube or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document abnormal blood counts or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia progression), and sample collection risks.
Procedural Considerations: Uses microscopy to count metamyelocytes, requiring labs with microscopes. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample clotting or contamination can affect results. Medications may alter counts, requiring correlation.
Clinical Significance: Elevated count suggests leukemia or marrow disorder, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal levels may require repeat testing.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Bone marrow biopsy, CBC, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False negatives possible with early disease.
References: ASH Guidelines, 2023; Blood, Dameshek W, 2022.
